WOW!!! EPIX läuft wieder! NEWS - 500 Beiträge pro Seite

[zip_3009]

14.08.2006 18:07
Epix near Vasovist approval in Australia
CAMBRIDGE, Mass. (AFX) - Epix Pharmaceuticals (Nachrichten) Inc., which develops drugs for magnetic resonance imaging, said Monday its Vasovist blood pool imaging agent is close to being approved in Australia.

The company said the Australian Drug Evaluation Committee recommended approval to the Therapeutic Goods Administration.

The imaging agent, which is injected into a patient and then used in conjunction with imaging technology, shows blood flow throughout the vascular system.

The U.S. Food and Drug Administration asked Epix to conduct another clinical trial on the agent in November 2005. A decision on the company's appeal has been delayed until September.

Vasovist is the company's lead product candidate.

Shares of the company added 24 cents, or 5.3 percent, to $4.77 in midday trading on the Nasdaq. Over the past 52 weeks, the stock had traded between $2.70 and $9.51, and is up 12 percent year-to-date.

[zip_3009]

ich bin nun kein grosser chartexperte, aber ich denke, wenn die 4,11€ vom februar geknackt werden, ist der weg nach oben offen

[zip_3009]

wer von euch hat eine meinung? sollte man jetzt noch einsteigen?

[zip_3009]

ja wieder grün in den usa

4,84$

[zip_3009]

EPIX Pharmaceuticals, Inc. Shareholders of EPIX and Predix Vote for Merger
EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) today announced that its shareholders have voted to approve the Company's merger with Predix Pharmaceuticals Holdings, Inc., which was previously announced on April 3, 2006, as well as each of the other proposals related to the merger. In addition, the shareholders of Predix also approved the transaction. The companies expect that the merger will close tomorrow, August 16th.

� The combined company will be known as EPIX, and is expected to continue to trade on NASDAQ under the symbol "EPIX". Following the closing of the transaction, management of the combined company will provide information for a conference call and webcast.

� "The vision we had when we initiated the merger with Predix can now start to become reality," stated Chris Gabrieli, Chairman of the Board of EPIX. "We are excited about the potential of the combined company, and look forward to the continuing progress of both EPIX's contrast agents and Predix's therapeutic compounds."

� About EPIX Pharmaceuticals

� EPIX Pharmaceuticals, Inc., based in Cambridge, MA, discovers and develops innovative pharmaceuticals for imaging that are designed to transform the diagnosis, treatment and monitoring of disease. EPIX uses its proprietary Target Visualization Technology(TM) to create imaging agents targeted at the molecular level, designed to enable physicians to use Magnetic Resonance Imaging (MRI) to obtain detailed information about specific disease processes. To receive the latest EPIX news and other corporate developments, please visit the EPIX website at www.epixpharma.com.

� About Predix

� Predix Pharmaceuticals Holdings, Inc., based in Lexington, MA, is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. Using its proprietary drug discovery technology and approach, Predix has advanced four internally-discovered drug candidates into clinical trials and has five additional programs in preclinical development and discovery targeting conditions such as generalized anxiety disorder, Alzheimer's disease, pulmonary hypertension (PH), PH associated with chronic obstructive pulmonary disease, obesity and cognitive impairment associated with Alzheimer's disease or schizophrenia. Additional information about Predix can be found on the company's website at www.predixpharm.com.

� This news release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that are based on current expectations of EPIX Pharmaceuticals' management. These statements relate to, among other things, expectations regarding EPIX Pharmaceuticals' continued trading on NASDAQ,, the timing of the consummation of the merger and related conference call thereafter, the timing and results of clinical trials involving Predix's drug candidates, the commercial success of EPIX Pharmaceuticals' imaging agents and the successful integration of EPIX Pharmaceuticals and Predix. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond EPIX Pharmaceuticals' control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: any failure to comply with federal and state statutes and regulations relating to EPIX Pharmaceuticals' products, including FDA requirements; the failure of EPIX Pharmaceuticals to satisfy FDA requests relating to EPIX Pharmaceuticals' products; the inability of EPIX Pharmaceuticals to successfully in-license products and/or technologies; the inability of EPIX Pharmaceuticals to identify and interest potential partners in its technologies and products, particularly EP-2104R; the inability of EPIX Pharmaceuticals to successfully defend itself against litigation, including any appeal or re-filing of the shareholder class action lawsuit; the inability to protect EPIX Pharmaceuticals' intellectual property and the cost of enforcing or defending EPIX Pharmaceuticals in litigation relating to intellectual property rights; EPIX Pharmaceuticals' or Predix's inability to satisfy the conditions of the merger; the risk that EPIX Pharmaceuticals' and Predix's businesses will not be integrated successfully; the combined company's inability to further identify, develop and achieve commercial success for new products and technologies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that the combined company may be unable to successfully secure regulatory approval of and market its drug candidates; the risks associated with reliance on outside financing to meet capital requirements; risks associated with Predix's new and uncertain technology; the development of competing systems; the combined company's ability to protect its proprietary technologies; patent-infringement claims; and risks of new, changing and competitive technologies and regulations in the U.S.

and internationally. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. EPIX Pharmaceuticals undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding these and other risks faced by EPIX Pharmaceuticals, see the disclosure contained in EPIX Pharmaceuticals' filings with the Securities and Exchange Commission, including but not limited to EPIX Pharmaceuticals' Form 10-K for the year ended December 31, 2005 and subsequent Forms 10-Q.



15.08.2006

[zip_3009]

RT USA 4,87$

[zip_3009]

über 4,90....jetzt wirds langsam interessant

[zip_3009]

neues halbjahreshoch

[zip_3009]

wenn wir diese woche über 5 dollar laufen, steht nichts mehr im weg!

[zip_3009]

sk 4,85$

+0,83%

[zip_3009]

EPIX Pharmaceuticals, Inc. EPIX and Predix Pharmaceuticals Complete Merger

� Board Approves Reverse Stock Split; Investor Conference Call Scheduled for August 23, 2006

� EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) announced today the completion of its previously announced merger with Predix Pharmaceuticals Holdings, Inc. Pursuant to the merger agreement, Predix merged with and into EPIX Delaware, Inc. and became a wholly-owned subsidiary of EPIX. The combined company will continue to operate as EPIX.

� "We are pleased that the shareholders of both EPIX and Predix approved the combining of the two companies and that the merger is now complete," stated Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX Pharmaceuticals. "This merger creates a biopharmaceutical company with a novel MRI angiographic agent, Vasovist(TM), approved in Europe, five internally-discovered clinical-stage product candidates and a deep pipeline of preclinical compounds. We believe these assets provide us with significant opportunities for near-term value creation similar to our collaborations with Amgen and Schering AG." � Andrew Uprichard, M.D., president of EPIX added, "I am excited about the breadth of talent and resources we have assembled that will enhance our ability to improve patients' lives by developing products that meet significant, unmet clinical needs and thereby drive significant shareholder value." � The combined company has a broad pipeline of product candidates, an experienced management team and approximately $114 million in cash and marketable securities as of June 30, 2006. Vasovist(TM), EPIX's novel blood pool imaging agent, which is marketed in Europe by Schering AG, has been recommended for approval in Australia, and is the subject of an appeal following two approvable letters from the U.S. Food and Drug Administration. In addition, the combined company has five drug candidates in clinical trials:

� -- PRX-00023 in Phase 3 for anxiety, with the results of this trial expected later this year;

� -- EP-2104R in Phase 2 for MRI imaging of arterial and venous blood clots;

� -- PRX-08066 in Phase 2 development for pulmonary hypertension associated with chronic obstructive pulmonary disease (CODP);

� -- PRX-03140, which has completed Phase 1b trials, is expected to enter Phase 2 in combination with Aricept(R) for Alzheimer's disease later this year; and

� -- PRX-07034 in Phase 1 and expected to be developed for the treatment of obesity and also for cognitive impairment (associated with Alzheimer's disease or schizophrenia).

� The combined company also has a portfolio of several pre-clinical product candidates, including a partnership with Amgen around preclinical compounds targeting S1P1 for the treatment of autoimmune diseases. EPIX has begun to initiate discussions to selectively license its later-stage products to larger pharmaceutical or biotechnology companies at a point where it can maximize the value of these products.

� Dr. Kauffman added, "With several milestones on the horizon, including the FDA's response to our appeal regarding Vasovist and the results from our Phase 3 clinical trial of PRX-00023 in patients with generalized anxiety disorder, we believe we will have continued momentum and significant growth opportunities going forward."

� Reverse Stock Split and Merger Consideration

� In connection with the merger, EPIX effected a 1-for-1.5 reverse stock split of its outstanding common stock. Accordingly, each Predix share (on an as-converted to common stock basis) was converted in the merger into the right to receive .826698 shares of EPIX common stock.

In addition, all outstanding Predix options and warrants were assumed by EPIX in the merger. The Predix stockholders, option holders and warrant holders are also entitled to receive their pro rata portion of an additional milestone payment of $35 million. Pursuant to the terms of the merger agreement, the board of directors has determined to pay $20 million of the milestone payment in cash on October 29, 2006. The remaining $15 million of the milestone will be paid in shares of EPIX common stock on October 29, 2007 except to the extent that such shares would exceed 49.99% of EPIX's outstanding shares immediately after such milestone payment when combined with all shares of EPIX issued in the merger and issuable upon exercise of all Predix options and warrants assumed in the merger.

� The post reverse-split common stock of EPIX is anticipated to start trading on the NASDAQ Global Market on August 17, 2006 under the symbol "EPIX." As a result of the merger and reverse stock split, a "D" will be appended to EPIX's NASDAQ trading symbol for the next 20 days.

� Investor Conference Call

� EPIX has scheduled an investor conference call for August 23, 2006 at 8:00 a.m. Eastern Time to provide an overview of the combined company and discuss its progress in key programs. The live webcast can be accessed by visiting the investor relations section of the Company's website at http://www.epixpharma.com. The call can be accessed by dialing 1-800-659-1966 (domestic) or 617-614-2711 (international) five minutes prior to the start time and providing the pass code 48005474. A replay of the call will be available on the EPIX website approximately two hours after completion of the call and will be archived for two weeks.

� About EPIX Pharmaceuticals

� EPIX Pharmaceuticals is a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has a blood-pool imaging agent approved and marketed in Europe (Vasovist(R)), and five internally-discovered drug candidates currently in clinical trials targeting conditions such as anxiety, depression, Alzheimer's disease, cardiovascular disease and obesity.

EPIX also has collaborations with leading organizations, including Amgen, Cystic Fibrosis Foundation Therapeutics, and Schering AG, Germany. For more information about EPIX, please visit the company's website at www.epixpharma.com.

� Forward-looking Statements

� This news release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that are based on current expectations of management. These statements relate to, among other things, expectations regarding our continued listing on the NASDAQ Global Market, the timing of the conference call following merger, the timing and results of clinical trials involving our drug candidates, the commercial success of our product candidates and strategic collaborations and the successful integration of EPIX Pharmaceuticals and Predix in the merger. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: any failure to comply with regulations relating to our products and product candidates, including FDA requirements; our failure to satisfy FDA requests relating to our products and product candidates; our inability to successfully in-license products and/or technologies; our inability to identify and interest potential partners in our technologies and products, particularly EP-2104R; our inability to successfully defend against litigation, including any appeal or re-filing of the shareholder class action lawsuit; our inability to protect our intellectual property and the cost of enforcing or defending our intellectual property rights; the risk that EPIX's and Predix's businesses will not be integrated successfully; our inability to further identify, develop and achieve commercial success for new products and technologies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully secure regulatory approval of and market our drug candidates; the risks associated with reliance on outside financing to meet capital requirements; risks associated with new and uncertain technology; the development of competing systems; and risks of new, changing and competitive technologies and regulations in the U.S. and internationally. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding these and other risks that we face, see the disclosure contained in our filings with the Securities and Exchange Commission, including our Registration Statement on Form S-4 (Registration No.

333-133513) relating to the merger.

[zip_3009]

wegen des splits wird ja heut in ffm nicht gehandelt. da kann ich mich aber schon über ein schönes plus freuen

[zip_3009]

08/21/2006

� EPIX has scheduled an investor conference call for August 23, 2006 at 8:00 a.m. Eastern Time to provide an overview of the combined company and discuss its progress in key programs. The live webcast can be accessed by visiting the investor relations section of the Company's website at http://www.epixpharma.com. The call can be accessed by dialing 1-800-659-1966 (domestic) or 617-614-2711 (international) five minutes prior to the start time and providing the pass code 48005474. A replay of the call will be available on the EPIX website approximately two hours after completion of the call and will be archived for two weeks.

� About EPIX Pharmaceuticals

� EPIX Pharmaceuticals is a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has a blood-pool imaging agent approved and marketed in Europe (Vasovist(TM)), and five internally-discovered drug candidates currently in clinical trials targeting conditions such as anxiety, depression, Alzheimer's disease, cardiovascular disease and obesity.

EPIX also has collaborations with leading organizations, including Amgen, Cystic Fibrosis Foundation Therapeutics, and Schering AG, Germany. For more information about EPIX, please visit the company's website at www.epixpharma.com.

� Note to Editors/Investors:

� As a result of the merger and reverse stock split, a "D" has been added to EPIX's NASDAQ trading symbol for 20 days following the closing of the merger on August 16, 2006.

[zip_3009]

und heute wieder schön ins plus gedreht!! aufwärts gehts!!!

[zip_3009]

hallo und mahlzeit...

epix wird in d ab sofort unter folgendem symbol gehandelt: A0KE6J

[zip_3009]

http://library.corporate-ir.net/library/91/917/91717/items/2…

[zip_3009]

wenn vasovist in den usa zugelassen wird, sollten wir hier viel höhere kurse sehen.

[cyberhai]

Die Aktie steht bei mir auch unter Beobachtung. Im August gab es Insiderkäufe, aber wahrscheinlich im Rahmen eine Kapitalerhöhung:

http://finance.yahoo.com/q/it?s=EPIX